Definitive Contract 75N93023C00014

Award Date 7/1/23

Potential Completion Date 6/30/25

Potential Value $4.5M

Federal Agency

National Institute of Allergy and Infectious Diseases

Awardee

Innovation Pathways, LLC

Ultimate Awardee

Not listed

NAICS Category

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

PSC Category

AN12 - Health R&D Services; Health Care Services; Applied Research

Federal Contract Vehicle

Set-Aside Type

No Set-Aside Used

Extent Competed

Full and Open Competition

Major Defense Program

Not listed

Pricing Type

Cost Plus Fixed Fee

Place of Performance

Palo Alto, CA 94301, USA

Solicitation Procedures

Negotiated Proposal / Quote

Number Of Offers Received

Legislative Mandate

Employment Eligibility Verification

National Interest Action

Not listed

Research Type

Not listed

Primary Consortia Member

Not listed

This is a $4,499,688.00 Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health, to Innovation Pathways, LLC to support the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury under the FDA Animal Rule. The contract has an ultimate completion date of June 30, 2025 and was awarded on July 1, 2023. It was competed under a Broad Agency Announcement (BAA) with no set-aside designation. The work aims to develop safe and effective medical countermeasures to mitigate and treat radiation injuries, as well as advance biodosimetry biomarkers and devices to inform triage and treatment strategies for mass casualty radiation incidents.

Generated 6/7/24, 10:24 AM

Name	Solicitation Number	Federal Agency	Type	Posted Date (Click to sort descending)
Development Of Anticeramide Treatment As A Novel Medical Countermeasure For Acute Effects Of Radiation Exposure	NIAID-BAA-75N93021R00019	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Award Notice 11/12	7/6/23, 12:32 PM
Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Bio-dosimetry Devices	IB2310_75N93021R00019	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Solicitation 4/12	3/4/22, 4:27 PM
Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Bio-dosimetry Devices	HHS-NIH-NIAID-BAA-75N93021R00019	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Pre-Solicitation 1/12	11/15/21, 10:31 AM
a microRNA Biodosimeter	NIAID-BAA-75N93021R00019	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Award Notice 12/12	7/6/23, 12:36 PM
Development of PLX-R18 Cell Therapy as a Countermeasure for Hematopoietic Acute Radiation Syndrome	NIAID-BAA-75N93021R00019	Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases	Award Notice 8/12	7/6/23, 12:12 PM

Mod #	Reason For Modification	Federal Obligation (Click to sort descending)	Date (Click to sort ascending)
P00003	Exercise an Option	$1.5m	6/6/24
P00002	Other Administrative Action	$0	5/15/24
Not listed	Not listed	$1.5m	6/29/23

Plans
Login

Blog